ASH 2015 | The Phase II clinical trial of ixazumib, the first oral proteasome inhibitor in MM
Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ provides an overview of a Phase II clinical trial of ixazomib, the first oral proteosome inhibitor to be approved for the treatment of multiple myeloma (MM). The clinical trial assessed the effects and safety of different doses of ixazomib, which showed to have considerable single-agent activity in the MM setting.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
Get great new content delivered to your inboxSign up